Opinion|Videos|November 5, 2024
Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01
This episode covers current sequencing strategies for NSCLC after targeted therapies and platinum chemotherapy, discusses the COMPEL trial with osimertinib, reviews OS and PFS end points from the TROPION-Lung01 study, examines hypotheses behind differential PFS responses in nonsquamous vs squamous NSCLC, and addresses what constitutes a clinically meaningful, durable response in heavily pretreated patients with advanced NSCLC and actionable genomic alterations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are your current sequencing strategies for after getting AGA, after getting approved targeted therapies, and after getting platinum chemotherapy?
- Please discuss the COMPEL trial results with osimertinib.
- Tell us about the OS and PFS end points of the TROPION-Lung01 study.
- What are some prevailing hypotheses that might explain the apparent differential PFS response and positive trend in OS with Dato-DXd among patients with nonsquamous vs squamous NSCLC histology?
- In your professional opinion, what length of time constitutes a clinically meaningful, durable response among heavily pretreated patients with advanced or metastatic NSCLC and actionable genomic alterations?
Advertisement
Related to this article
Sapanisertib and serabelisib plus paclitaxel received FDA fast track designation for pretreated advanced PI3K/AKT/mTOR pathway–altered endometrial cancer.
Lisa Niswander, MD, PhD, of Roswell Park, is investigating ways to combine CAR T cells and a new class of targeted cancer drugs for younger leukemia.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
UGN-103, a next-generation mitomycin formulation built on the ZUSDURI foundation, is supported by three-month CR and six-month DOR data from the phase 3 UTOPIA trial.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
No efficacy benefit was found in adding SBRT to dual checkpoint blockade, though a subset of patients responded to nivolumab plus ipilimumab.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.
Data from EXCALIBER-RRMM supported FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in R/R multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Viansone on ADC Sequencing in Metastatic HER2+ Breast Cancer
5